COVID‑19 May Be Helping Superbugs Hide in Our Noses and Throats

When most of us think about COVID‑19, the image that pops up is a feverish cough or a lingering loss of smell. Few would guess that the virus might also be giving a covert boost to bacteria that already know how to dodge our medicines.

A team of Indian scientists recently published a paper in Current Microbiology that throws exactly that curveball. By analysing 95 upper‑respiratory samples from central India with shotgun metagenomic sequencing, they discovered that the noses and throats of COVID‑19 patients harboured a noticeably richer “resistome” – the collection of antibiotic‑resistance genes – than the same sites in healthy, COVID‑negative volunteers.

To put it plainly, the genetic markers that let bacteria shrug off antibiotics were more abundant in the infected group. Out of 22 resistance genes that differed between the two cohorts, 21 were found in higher quantities among the COVID‑positive individuals.

What kind of bacteria are we talking about? The genes were linked to familiar culprits such as Escherichia coli, Klebsiella pneumoniae and Staphylococcus aureus. These microbes are not strangers; they are behind everything from uncomplicated urinary tract infections to life‑threatening sepsis and neonatal meningitis.

It would be a mistake, however, to read this as proof that the virus magically creates antibiotic resistance. The researchers are careful to say the infection seems to reshape the microscopic neighbourhood in our respiratory tract, making it more hospitable to bacteria that already carry resistance genes.

“Mapping the resistome in COVID‑19 patients is still a relatively new field,” explains Dr Krishna Khairnar, head of environmental epidemiology at CSIR‑NEERI and a co‑author of the study. “Our data show distinct SARS‑CoV‑2‑associated changes, with an enrichment of multiple AMR genes tied to opportunistic pathogens.”

In other words, the virus doesn’t hand‑out resistance; it simply nudges the balance, allowing the hard‑ier microbes to thrive while the more vulnerable ones fall by the wayside. This mirrors what clinicians have long observed: after a viral cold or flu, secondary bacterial infections can be harder to treat, especially if antibiotics have already been prescribed.

Speaking from a clinical angle, Dr Rajeev Jayadevan of Kerala points out a crucial caveat. “The study didn’t account for prior antibiotic use,” he says. “People may have taken a course of antibiotics before their COVID‑19 test, and that alone could explain the higher resistance gene load.” He adds that similar patterns have been seen with other respiratory viruses, so we shouldn’t jump to blaming SARS‑CoV‑2 alone.

Nevertheless, the findings ring an alarm bell. India already grapples with a heavy burden of antimicrobial resistance – an estimated 10.7 lakh infections with drug‑resistant bacteria in 2021 alone, and somewhere between 3 lakh and 10.4 lakh deaths in 2019 linked to AMR, according to the GRAM Project.

While the study didn’t track whether the participants actually developed bacterial infections later on, it provides an early warning sign. If the breath‑holding bacteria in our airways are already equipped with a stronger genetic arsenal, any subsequent infection could require more potent, perhaps last‑resort antibiotics.

That’s why experts like Dr Khairnar stress the need for metagenomic surveillance as a public‑health tool. By keeping an eye on the resistome across populations, authorities can fine‑tune antibiotic‑stewardship programmes and perhaps intervene before a superbug outbreak takes hold.

So the next time you hear about COVID‑19’s many long‑term sequelae, spare a thought for the tiny, invisible world living in your nose and throat. The virus may be reshaping that ecosystem in ways we are only beginning to understand – and those changes could have very real implications for how we treat infections in the months and years ahead.